Clinical Trial Update: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update notes that participants who previously enrolled in an elotuzumab study may continue receiving treatment, and the study is listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED